Evidence map›Paper›PMID 39753965›Full record

ArticleNature medicine2025

Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir.

M Ali Rai, Jana Blazkova, Lela Kardava, Jesse S Justement, Victoria Shi, Maegan R Manning, Aniqa Shahid, Winnie Dong, Brooke D Kennedy, Adeline B Sewack and 14 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

M Ali RaiLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Jana BlazkovaLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-6000-202X
Lela KardavaLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Jesse S JustementLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Victoria ShiLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Maegan R ManningLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Aniqa ShahidFaculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Winnie DongBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Brooke D KennedyLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-7146-6380
Adeline B SewackLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Jeanette HigginsLeidos Biomedical Research, Frederick, MD, USA.
Clarisa M BucknerLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Kathleen GittensCritical Care Medicine Department, Clinical Center, NIH, Bethesda, MD, USA.
Raymond E WestDepartment of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA.
Aaron S DevanathanDepartment of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-2778-3725
Ralph MangusanHIV and AIDS Malignancy Branch, National Cancer Institute, NIH, Bethesda, MD, USA.
Kathryn LurainHIV and AIDS Malignancy Branch, National Cancer Institute, NIH, Bethesda, MD, USA.
Ramya RamaswamiHIV and AIDS Malignancy Branch, National Cancer Institute, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-5709-4675
Robert YarchoanHIV and AIDS Malignancy Branch, National Cancer Institute, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-3057-1395
Michael C SnellerLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Alice K PauDivision of Clinical Research, NIAID, NIH, Bethesda, MD, USA.
Zabrina L BrummeFaculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.ORCID http://orcid.org/0000-0002-8157-1037
Susan MoirLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-0163-6911
Tae-Wook ChunLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA. twchun@nih.gov.ORCID http://orcid.org/0000-0001-5153-7340

Funding

REACH: Research Enterprise to Advance a Cure for HIVUM1AI164565 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Marina Caskey, R. Brad Jones · 2021 to 2026
$32.9M
Clinical Trials of Patients with AIDS-Related MalignanciesZIABC010888 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI YARCHOAN, ROBERT · 2009 to 2025
$20.6M
Role of Viral Reservoirs in the Pathogenesis of HIV DiseaseZ01AI000851 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI FAUCI, ANTHONY S. · 1999 to 2008
$1.7M
Small Molecule Biomarker Core: TSQ Altis LC-MS/MSS10OD028540 · OD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NOLIN, THOMAS DOUGLAS · 2020 to 2020
$429k
Intramural NIH HHS Z01 AI000851Intramural NIH HHS ZIA BC010888NIAID NIH HHS UM1 AI164565NIH HHS S10 OD028540
6 · The paper itself

Abstract

The clinical management of people with multidrug-resistant (MDR) human immunodeficiency virus (HIV) remains challenging despite continued development of antiretroviral agents. A 58-year-old male individual with MDR HIV and Kaposi sarcoma (KS) was treated with a new antiretroviral regimen consisting of anti-CD4 domain 1 antibody UB-421 and capsid inhibitor lenacapavir. The individual experienced delayed but sustained suppression of plasma viremia and a substantial increase in the CD4

Indexed as

Anti-HIV AgentsDrug Resistance, Multiple, ViralHIV-1HIV InfectionsAcetamidesAntibodies, Monoclonal, HumanizedCD4 AntigensCD4 Lymphocyte CountHumansIndazolesMaleMiddle AgedAcetamidesAntibodies, Monoclonal, HumanizedAnti-HIV AgentsCD4 AntigensIndazoleslenacapavir

Identifiers

PMID39753965
PMCPMC12120854

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.